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MEDICINE

Uncertain Influences: Genetics,
Pathology, and Alzheimer’s Disease
BY SUMITA STRANDER ’18

Introduction
Alzheimer’s disease (AD) is a progressive
neurodegenerative disease that primarily affects
individuals above the age of 65 and is often
associated with memory loss, one of its chief
symptoms. Although it was first discovered by
Alois Alzheimer in 1906, AD has only recently
garnered attention proportionate to the impact
it is expected to have as the world’s population
ages at increasing rates (National Institute
on Aging, 2016). Despite the certainty of this
its importance, there is much the medical and
scientific communities do not know about the
etiology of this disease. This paper will discuss a
few of the reasons for this lack of knowledge by
specifically describing the definite but unclear
influence of genetics and pathology on the
clinical symptoms of AD.
As previously mentioned, its hallmark
symptom is memory loss, specifically the
inability to retain novel information (National
Institute on Aging, 2016). Other symptoms
include disorientation, problems with speaking
and swallowing, and behavioral changes, the
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last of which are often the most burdensome
on the individual’s relationships with others
(National Institute on Aging, 2016). AD is the
most common type of dementia, and currently
affects over 5 million Americans (National
Institute on Aging, 2016).

Figure 1: High magnification
micrograph showing
Alzheimer type II astrocytes.
Source: Wikimedia Commons
(Credit: Nephron)

Understanding the Disease
Given its current and expected future
prevalence, there is a clear need for an
understanding of the underlying causes of
this disease, for it is what occurs within
(and beyond) the human body that leads to
these devastating symptoms. Indeed, many
researchers have responded swiftly to this
call to arms: a search on PubMed’s database
using the keywords “Alzheimer’s disease”
indicated that 7,617 articles were published on
this topic in 2016 alone. Despite this recently
demonstrated scientific interest, the largest
questions of influence remain. Two of the major
questions that will be explored in this paper
involve pathology and genetics.
Questions about the influence of a disease’s
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Figure 2: Auguste D, the first
patient diagnosed with the
disease that would come to
be named after the physician
Alois Alzheimer.
Source: Wikimedia Commons

pathology often seem unnecessary, for it is the
very study that is pathology seeks to explain
the causes of clinical symptoms. But when the
nature of the pathology itself is complex, the
matter becomes more complicated. Here, the
symptoms of AD are caused by the large-scale
death of neuronal cells in the brain, causing
what often appears to be a shrunken version of
the “normal” human brain (National Institute on
Aging, 2016). However, what is the cause (i.e.
pathogenesis) of this sweeping cell loss? When,
how, and why does this pathology result? While
there are no definite answers to this question,
many experts would bring up two compounds
with measurable physical presence in the brains

of those with AD: amyloid-beta and tau, often
collectively deemed, “plaques and tangles.”
Despite their noted association with AD, these
proteins have been subject to many questions
their specific influence. Amyloid-beta has
received the majority of the attention, and will
be further described below.
Amyloid-beta (Aβ) is a protein found in the
form of extracellular plaques, and is thought
to be largely unique to AD (Agamanolis, 2016).
Over a century since the disease’s discovery, the
detection of Aβ is still used to make a definitive
diagnosis upon autopsy because. Barring recent
technological advances, there has not existed a
means of observing these plaques in living tissue.
Despite not offering diagnostic assistance, this
method of studying Aβ has allowed scientists
to characterize the protein and has resulted
in a few important claims frequently made.
First, Aβ is a transmembrane protein that is
also a segment of a much larger protein called
Amyloid Precursor Protein (APP), whose
function in the body has yet to be determined
(Agamanolis, 2016). When APP is improperly
cleaved by a pair of enzymes, the product is
Aβ, which is then able to accumulate and form
among cells. In addition to simply accumulating
in the brain, Aβ is also dangerous to neurons
in a few specific ways. First, it disrupts long
term potentiation, a process that strengthens
connections between communicating neurons
(Purves et al., 2001). Second, it harms synapses,
the physical spaces that link neurons (Purves et
al., 2001). Ultimately, the toxicity of Aβ plaques
can result in death of neurons specifically in
areas of the brain associated with functions
impaired by AD (Agamanolis, 2016). The entire
process, beginning with APP and ending with

Figure 3: Amyloid-beta
plaques observed in the
brain of an individual with
Alzheimer’s disease.
Source: Wikimedia Commons
(Credit: User KGH)
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clinical symptoms of AD, is often called the
“amyloid cascade hypothesis.”

Weaknesses of the Amyloid
Cascade Hypothesis
Despite this logical link, there are a few
critical findings that the amyloid cascade
hypothesis has been unable to explain thus far.
Perhaps the most surprising is that up to 40%
of elderly without dementia have been shown
to possess AD pathology (Morris, Clark, &
Vissel, 2014), sometimes including Aβ at levels
comparable to those of individuals with clinical
symptoms of dementia (Swerdlow, 2007). How
is this consistent with the link clearly explained
by the amyloid cascade hypothesis? There
are several possibilities. One is that there are
multiple forms of Aβ, and only one—or some—is
responsible for symptoms. Another is that Aβ
does not actually cause symptoms at all, but is
instead produced by the process that does cause
them (Morris, Clark, & Vissel, 2014). Yet another
option is that other factors, perhaps external
to the brain, counteract the development of
symptoms that would normally occur due
to Aβ accumulation. This third possibility is
heavily implicated with the theory of “cognitive
reserve,” which suggests that individuals may
accrue tolerance for AD pathology over time
based on various lifestyle features (Morris,
Clark, & Vissel, 2014).
Clearly, this finding indicates a need for
resolution among experts. Another finding
making a similar demand is the high failure rate
of pharmaceutical drug trials that take as their
basis the influence of Aβ. A study examining
drug trials between 2002 and 2012 determined
out of 244 Alzheimer’s drugs tested in 413 trials,
only one was eventually approved, resulting in a
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failure rate of 99.6% (Burke, 2014). Furthermore,
these pharmaceuticals often seem to remove
the physical traces of Aβ plaques in affected
individuals, yet their symptoms remain. To
explain this finding, some have essentially argued
that removing amyloid after clinical symptoms
emerge is too late, and that if these drugs were
administered earlier, perhaps they would have
more success (Burke, 2014). Using this same
reasoning, the finding above—that individuals
without dementia can also show pathology—
can also be explained: maybe these individuals
were on track to develop symptomatic AD had
they not died before its onset (Morris, Clark, &
Vissel, 2014). This assertion is complicated, and
almost every claim or theory in this field, calls
for additional refinement.
In a related vein, there are many important
questions regarding the influence of genetics
on the development of AD symptoms. The role
of genetics cannot be adequately explained
without first understanding the division
between two types of Alzheimer’s disease: early
onset (EOAD) and late onset (LOAD). EOAD
comprises roughly 5% of all AD cases, and can
affect individuals at a much younger age range
than LOAD (Agamanolis, 2016). Beyond the
time of onset, these subtypes differ primarily in
their connections with genetics: EOAD has been
found to be caused genetic mutations, whereas
no such causal link has been found for LOAD
(Hutton, Pérez-Tur, & Hardy, 1998).
Specifically, EOAD is caused by mutations
in the genes that directly affect Aβ production.
One set of mutations is on the gene that codes
for APP itself, a gene found on chromosome
21; another, more common variety, involves
mutations are on two presenilin genes on
chromosome 14, genes that are thought to

Figure 4: A healthy brain (left)
compared with the shrunken
brain characteristic of
Alzheimer’s disease (right).
Source: Wikimedia Commons
(Credit: Garrondo)

“Perhaps the most
surprising is that
up to 40% of elderly
without dementia
have been shown
to possess AD
pathology.”
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Figure 5: A typical brain
image taken using Positron
Emission Tomography (PET) of
an individual with Alzheimer’s
disease.
Source: Wikimedia Commons
(Credit: National Institutes of
Health)

“One [unanswered
question] concerns
the heterogeneity
of ApoE’s influence.
Specifically, most
studies conducted...
predominantly
rely on Caucasian
subjects.”

also influence Aβ production (Hutton, PérezTur, & Hardy, 1998). Thus, through direct or
indirect impact, these mutations in EOAD are
themselves crucial for the maintenance of the
amyloid cascade hypothesis. Furthermore,
they are inherited in an autosomal dominant
pattern, meaning that only one inherited copy
is sufficient for an offspring to develop the
disease (Hutton, Pérez-Tur, & Hardy, 1998).
The complexity emerges, however, when
examining the other 95% of AD cases, for this
straightforward pattern ceases to hold in LOAD.
Thus far, no genetic mutations have found to be
definitive causes of LOAD; instead, researchers
have been able to identify a susceptibility gene:
ApoE.
ApoE controls production of the ApoE
protein, which is thought to be involved in
repairing the brain after damage (Hutton, PérezTur, & Hardy, 1998). It is found on chromosome
19 and exists in three forms, or alleles: ϵ2, ϵ3,
and ϵ4. Of these, the ϵ4 allele has been shown
to increase susceptibility of AD, and to do so
in a “dose-dependent manner,” meaning that
inheriting two copies of this allele increases
risk more than inheriting one copy (ErtekinTaner, 2007). This was demonstrated in a study
that found that 55% of subjects with two copies
developed AD by age 80, compared with 27% of
subjects with an ϵ3/ ϵ4 pair, and with 9% of those
with two copies of ϵ3 (Ertekin-Taner, 2007).

have hypothesized that this observation could
be due to genetic and environmental factors
and interactions that affect distinct populations
differently. Ultimately, it has been estimated
that the ApoE ϵ4 allele imparts a risk of 2070%, a range that evokes the uncertainty
characterizing not only this issue but the field in
general (Ertekin-Taner, 2007).
The questions that arise in determining the
cause(s) of AD are complicated and multifaceted.
Those involving pathogenesis and genetics are
some of the most studied, but do not exhaust all
the avenues of inquiry researchers and clinicians
are taking. For example, many have turned
towards a closer examination of environmental
factors, and others have chosen to focus not
on the causality of AD but rather on equally
important questions regarding the quality of
life of those living with dementia. Each area is
critical in understanding this highly complex
and common disease, and one can hope that
with resources, time, creativity, and persistence,
strides can be made in the near future. D
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Conclusion
Although this evidence is quite compelling,
there are nevertheless unanswered questions.
One concerns the heterogeneity of ApoE’s
influence. Specifically, most studies conducted—
including the one mentioned above—
predominantly rely on Caucasian subjects.
Studies that have focused on African-American
and Hispanic populations have found a much
weaker association, or even no association at all
in some cases (Ertekin-Taner, 2007). Researchers
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